8-K: COMPASS PATHWAYS Achieves Primary Endpoint in Landmark Phase 3 Trial for Treatment-Resistant Depression

COMPASS PATHWAYS PLC announced the successful achievement of the primary endpoint in its Phase 3 COMP005 trial for treatment-resistant depression, demonstrating a highly statistically significant reduction in symptom severity with its COMP360 psilocybin formulation.

Summary

• COMPASS PATHWAYS PLC successfully achieved the primary endpoint in its Phase 3 COMP005 trial, which evaluates COMP360, a synthetic psilocybin formulation, for treatment-resistant depression (TRD).
• A single 25 mg dose of COMP360 demonstrated a highly statistically significant reduction in symptom severity compared to placebo (p<0.001) at week 6, as measured by the Montgomery-sberg Depression Rating Scale (MADRS).
• The mean treatment difference in MADRS scores was -3.6 points, with a 95% confidence interval of [-5.7, -1.5], indicating a clinically meaningful difference.
• Safety data from both the COMP005 and parallel COMP006 studies are consistent with previous COMP360 studies, showing no new or unexpected safety findings and no clinically meaningful imbalance in suicidality.
• The COMP005 trial involved 258 participants with moderate-to-severe depression across 32 sites in the United States.
• The COMP006 trial, running in parallel, plans for 568 participants from North America and Europe and compares different fixed doses of COMP360.

Sentiment

Score: 9

Explanation: The successful achievement of the primary endpoint with highly statistically significant and clinically meaningful results for a novel treatment in TRD is a major positive milestone. The consistent safety profile further strengthens the positive outlook. However, the data is preliminary, FDA review is pending, and future funding needs are highlighted as a risk.

Positives

• Successful achievement of the primary endpoint in the Phase 3 COMP005 trial for treatment-resistant depression.
• Highly statistically significant reduction in symptom severity (p<0.001) with a single 25 mg dose of COMP360.
• Clinically meaningful difference of -3.6 points in MADRS scores at the primary endpoint.
• Safety findings are consistent with previous studies of COMP360, with no new or unexpected safety issues reported.
• No evidence of a clinically meaningful imbalance in suicidality between treatment arms in either COMP005 or COMP006 studies.

Negatives

• The U.S. Food and Drug Administration (FDA) has not yet reviewed the data, meaning regulatory approval is not guaranteed.
• The results are preliminary, and full results or results from the ongoing COMP006 trial may not be consistent with these initial findings.

Risks

• Clinical development is a lengthy and expensive process with uncertain outcomes, and clinical trials may be delayed or terminated and may be more costly than expected.
• The full results and safety data from the COMP005 study or the results and safety data from the COMP006 study may not be consistent with the preliminary results to date.
• The Company needs substantial additional funding to achieve its business goals, and if it is unable to obtain this funding when needed and on acceptable terms, it could be forced to delay, limit, or terminate its clinical trials.
• The Company's efforts to obtain marketing approval from applicable regulatory authorities in any jurisdiction for COMP360 may be unsuccessful.

Future Outlook

The company plans to discuss the preliminary COMP005 data with the U.S. Food and Drug Administration (FDA). They anticipate sharing 26-week data for COMP005 once all participants in Part A of the COMP006 trial have completed their phase. The 26-week data from the COMP006 trial is expected in the second half of 2026. The pivotal Phase 3 program aims to support future regulatory filings and approvals for COMP360 in TRD.

Management Comments

• "Based on the latest review of the data for the 005 and 006 studies, safety findings are consistent with previous studies of COMP360 and there are no new or unexpected safety findings. From this review of the data, there is no evidence of a clinically meaningful imbalance between treatment arms in suicidality in either study." (Statement from the DSMB chair, as reported by the company).

Industry Context

This announcement is highly significant for the psychedelic medicine industry, particularly for the development of psilocybin-based therapies for mental health conditions. Treatment-resistant depression (TRD) represents a large unmet medical need, and a successful Phase 3 trial for a novel psychedelic compound could pave the way for new treatment paradigms. This positive data positions COMPASS PATHWAYS as a leader in the clinical development of psychedelic-assisted therapies, potentially accelerating broader acceptance and regulatory pathways for similar compounds.

Stakeholder Impact

• Shareholders: Positive clinical trial results are highly likely to increase investor confidence and potentially the share price, though future funding needs and regulatory risks remain.
• Patients (TRD): The successful trial offers significant hope for a new and effective treatment option for a difficult-to-treat condition.
• Employees: Positive progress in clinical trials can boost morale and job security within the company.
• Regulatory Authorities (FDA): Will be reviewing the data for potential marketing approval, which could set a precedent for psychedelic-assisted therapies.

Next Steps

• Discuss preliminary COMP005 data with the U.S. Food and Drug Administration (FDA).
• Share 26-week data for COMP005 once all participants in Part A of the COMP006 trial have completed their phase.
• Await 26-week data from the COMP006 trial, which is expected in the second half of 2026.
• Potentially pursue regulatory filings and approvals based on the pivotal Phase 3 program.

Key Dates

Recommendation

Keywords

psilocybin, COMP360, treatment-resistant depression, TRD, Phase 3 trial, clinical trial, mental health, psychedelic medicine, COMPASS PATHWAYS, COMP005, COMP006, FDA, MADRS, drug development